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Background and aim: The liver shows remarkable regeneration ability after damage or resection. The
main stimulant for hepatic regeneration is resection. Erythropoietin (EPO), which was initially used for
anemia therapy, is today known as a general tissue protector owing to its anti-inﬂammatory, anti-
oxidant, anti-apoptotic, and angiogenic properties. This study aims to investigate the effect of systemi-
cally administered EPO on liver regeneration after partial hepatectomy.
Methods: Forty-eight male Wistar albino rats were randomly split in two groups A and B consisting of 24
rats each. Standard 70% hepatectomy was performed on the rats in group A. The same surgical procedure
was performed on the rats in group B, and they were additionally administered 3000 U/kg/subcutaneous
EPO. The rats were sacriﬁced 24, 48, and 72 h after resection. The groups were compared in terms of
biochemical, morphological, and histopathological parameters.
Results: The biochemical results showed that the administration of EPO decreased aspartate amino-
transferase levels signiﬁcantly (p < 0.05) at 24 h after hepatectomy. A comparison of the groups in terms
of relative liver weight showed that EPO-treated groups exhibited a statistically signiﬁcant increase
(p < 0.05) for all three time periods. Histopathology results showed that in the EPO-treated groups, the
mitosis index at 48 and 72 h, double nuclei cell number at 72 h, and proliferating cell nuclear antigen
ratio at 48 h showed a signiﬁcant increase (p < 0.05).
Conclusion: Our study showed that systemically administering high-dose EPO increases regeneration by
affecting the biochemical, morphological, and histopathological parameters after liver resection.
 2012 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
One of the remarkable features of the liver is its endogenous
capacity to proliferate and regenerate. Currently, the only curative
option for themanagement of many primary and secondary hepatic
tumors is regular or irregular resections. Nevertheless, liver resec-
tions should be limited in order to preserve a sufﬁcient amount of
remnant functional liver tissue. Otherwise, excessive resections
may lead to liver failure and a fatal clinical course within a few days
of surgery.1e3 Acute tissue loss is poorly tolerated by the liver
because it causes impaired function and decreased regeneration
ability.4 Great advances in the understanding of the mechanisms
underlying hepatic regeneration have made it possible to develop9; fax: þ90 412 2488523.
ciates Ltd. Published by Elsevier Lta variety of strategies to counteract postoperative liver insufﬁ-
ciency.5,6 Two-stage hepatectomies and preoperative portal venous
embolizations are the two most common approaches used for
increasing the number of patients feasible for extended liver
resections.5 However, no deﬁnitive and established treatment
strategy with proven efﬁciency for increasing the regeneration
capacity of the remaining liver after major hepatic surgery is
currently available. Various experimental studies have been con-
ducted to identify substances that have the potential to maximize
hepatocyte proliferation and liver regeneration.7e9 Within this
context, recombinant human erythropoietin (rHuEPO) seems to be
a promising agent and a valid approach with a distinct safety
margin for human use.10 This hormone has been shown to regulate
the activity of the transformation of erythroid progenitors to
mature erythrocites by binding to its special cell surface receptors
in the bone marrow.11 Today, the premise that EPO is essential only
for erythropoiesis has changed owing to studies that have shownd. All rights reserved.
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than the liver and the kidney, such as the brain, heart, and pancreas
as well as in vascular, gastrointestinal, and reproductive
systems.12,13 Beyond its hematopoietic function, EPO has also been
recognized as an anti-apoptotic, mitogenic, and tissue-protective
pleiotropic cytokine.14e16 Lately, studies have focused on the
effect of EPO on liver regeneration.17,18 Owing to the various func-
tions of EPO, we considered that it might have a positive effect on
liver regeneration in hepatic resections. To provide evidence for
this hypothesis, we measured the relative liver weight (RLW) and
determined themitosis index (MI), double nuclear cell number, and
marked proliferated cell nuclear antigen (PCNA) ratio through
histopathology. We also measured the aspartate aminotransferase
(AST), gamma glutamyl transferase (GGT), and alkaline phospha-
tase (ALP) serum levels in an experimental model of hepatic
resection in rats.
2. Materials and methods
This experimental study is performed with the permission of the ethics
committee of the Zonguldak Karaelmas University Medical Faculty, Experimental
Medicine and Animal Laboratory. Forty-eight male Wistar albino rats of 20 weeks of
age and with weights of 170e210 g (average weight:189 g) are used in the study.
Standard rat chow and tap water is given to the rats during both pre- and post-
operative periods.
2.1. Experimental design
The rats are randomly divided into two groups A and B of 24 rats each. Each
group is divided into three subgroups “1,” “2,” and “3” according to the time of
sacriﬁce.GROUP A: 70% hepatectomy is carried out
GROUP A-1: sacriﬁced at 24 h (n:8)
GROUP A-2: sacriﬁced at 48 h (n:8)
GROUP A-3: sacriﬁced at 72 h (n:8)
GROUP B: 70% hepatectomy is carried out and 3000 IU EPO/kg-subcutaneously
EPO (Eprex Janssen-Cilag) is administered
GROUP B-1: sacriﬁced at 24 h (n:8)
GROUP B-2: sacriﬁced at 48 h (n:8)
GROUP B-3: sacriﬁced at 72 h (n:8)2.2. Surgical procedure
Anesthesia was provided by a dose of 90 mg/kg intramuscular ketamine
(Ketalar 50 mg Flakon, Eczacıbası, _Istanbul), and the weights of the rats were
recorded. A partial 70% hepatectomy resecting the left and median lobes of the liver
according to Higgins and Anderson’s method was performed.19 The excised partial
hepatectomy specimens were weighed and recorded. The abdomenwas closed with
continuous stitches using atraumatic silk sutures (Ethicon Atraumatic Silk Suture
3-0, Johnson&Johnson JNTL, Brussels, Belgium) and cleaned with povidone iodine.
The rats in Group B were administered a single-dose 3000 U/kg subcutaneous EPO
(Eprex Janssen-Cilag) injection after the abdominal skin was closed subsequent to
liver resection. All surgical operations were performed under sterile conditions. TheTable 1
Levels of biochemical parameters and relative liver weight in various groups.
Group A1 B1 P A2
AST(IU/L) 899.3  65.6 573.9  294.1* .009 731.5  285.8
ALP(IU/L) 454.1  113.3 527.2  294.0 .549 360.0  162.6
GGT(IU/L) 144.2  99.6 110.0  75.2 .452 71.0  77.2
RLW 40.6  11.8 51.2  6.5 .030 52.7  4.6
AST: Aspartate aminotransferase, ALP: Alkaline phosphatase, GGT: Gamma-glutamyl tra1st subgroups (A-1 and B-1) were sacriﬁced at 24 h; the 2nd subgroups (A-2 and B-
2), at 48 h; and the 3rd subgroups (A-3 and B-3), at 72 h after resection. During
sacriﬁce, laparotomies and thoracotomies were performed on the rats, and intra-
cardiac blood was taken for biochemical investigations. The liver was completely
excised and weighed; then, it was placed in 10% formaldehyde solution in order to
protect it for further histopathological examinations.
2.3. Biochemical parameters
The blood drawn from the rats into gelled biochemistry tubes was centrifuged at
3500 rpm for 5 min, and the derived serumwas stored at 80 C until the AST, GGT,
and ALP levels were studied. The measurements were performed using AST, GGT,
and ALP kits manufactured by Bio Systems Reagents and Instruments (Spain) and
a Shimadzu SPD-20AV UV detector.
2.4. Morphological parameters
2.4.1. Relative liver weight
The resected liver weight (B) was subtracted from the total liver weight (A).
The obtained value was then subtracted from the liver weight at sacriﬁce (C)
divided by the total liver weight, and this value was multiplied by 100 to ﬁnd the
liver regeneration rate.20 The total liver weight was taken as 3.4% of the total rat
weight,21 and the results were expressed in percentages as follows: RLW(%) ¼
[C(AB)/A]  100.
2.4.2. Histopathological parameters
1. Mitosis index (MI): MI is inspected in hematoxylin-eosin (H&E) stained
sections of parafﬁn blocks obtained from liver tissue preserved in 10% form-
aldehyde. The number of mitotic hepatocytes at the 30 sites where mitosis was
found most commonly was expressed as a ratio of 1000 cells.22
2. Double nuclei cells: Double nuclei cells were inspected in H&E stained
sections of parafﬁn blocks obtained from liver tissue preserved in 10% form-
aldehyde. The numbers of total hepatocytes and double nuclei hepatocytes at
30 sites where double nuclei cells were found most commonly were expressed
as a ratio of 1000 cells.
3. Ratio of marked cells with proliferating cell nuclear antigen (PCNA): Liver
tissue preserved in 10% formaldehyde was embedded in parafﬁn, following
which 5-mm-thick cross sections were taken from the specimens and
immunohistochemical examination was performed using a PCNA kit (Neo-
markers, Fremont, USA). The total numbers of PCNA stained cells and hepa-
tocytes at 30 magniﬁcation sites were found and expressed as a ratio of 1000
cells.22
2.5. Statistical evaluation
The statistical average and standard deviation is shown in tables using numbers
and percentages. The ManneWhitney U-test was used in comparing groups of two.
The statistical signiﬁcance of the results was evaluated as p < 0.05. All data were
prospectively recorded in the created SPSS database, and the analyses were per-
formed using the statistical package program SPSS for Windows 11.0 (SPSS Inc.,
Chicago, IL, USA).3. Results
3.1. Biochemical parameter levels
The average values, standard deviations, and standard error
ratios of various biochemical parameters are shown in Table 1. After
biochemical examination, it was determined that at 24 h, the AST
levels were lower in the EPO-treated group compared to those in
the untreated group (p ¼ 0.009) (Table 1).B2 P A3 B3 P
841.6  88.6 .347 544.4  239.5 483.7  217.6 .604
557.8  503.6 .311 733.1  293.4 920.5  389.4 .295
96.6  43.9 .454 55.7  26.0 70.4  41.6 .412
60.6  5.5 .008 49.8  10.6 62.6  12.9 .049
nsferase, RLW: Relative liver weight.
Fig. 1. RLW was determined to be higher in the EPO-treated groups in all three time
periods (*p < 0.05).
Fig. 2. A, B, C. Mitosis index was higher at 48 and 72 h in the EPO-treated groups
(**p < 0.001) (A), appearance of mitotic activity at 48 h after liver resection (H&E 100x)
(B), and increase in mitotic activity 48 h after EPO treatment (H&E 200x) (C). Blue
arrows indicate increased mitotic activity.
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At 24, 48, and 72 h, when RLWwas compared between the EPO-
treated (B1-B2-B3) and untreated (A1-A2-A3) groups, it was found
to increase in all three time periods with a statistically signiﬁcant
level (0.030, 0.008,and 0.049,respectively) (Table 1 and Fig. 1).
3.3. Histopathological parameters
With regard to MI, that of Group B2 and B3 was found to be
higher than that of Group A2 and Group A3, respectively, with
a statistically signiﬁcant difference (p < 0.001) (Fig. 2AeC). With
regard to the double nuclei cell number, that of Group B3was found
to be higher than that of Group A3 with a statistically signiﬁcant
difference (0.018) (Fig. 3AeC).With regard to the PCNA ratio, that of
Group B2 was found to be higher than that of Group A2 with
a statistically signiﬁcant difference (p < 0.001) (Fig. 4AeC). A
comparison of the groups’ histopathological parameters is
summarized in Table 2.Fig. 3. A, B, C. Double nuclei cell number was higher at 72 h in the EPO-treated groups
(*p ¼ 0.018) (A), appearance of double nuclei cells at 72 h after liver resection (H&E
100x) (B), increase in double nuclei cell number 72 h after EPO treatment (H&E 200x)
(C). Blue arrows indicate increased double nuclei cell number.
Fig. 4. A, B, C. Calculated PCNA staining ratios were higher at 48 h in the EPO-treated
group (**p < 0.001) (A), appearance of PCNA stained cells at 48 h after liver resection
(H&E100x) (B), increase in PCNA staining ratios 48 h after EPO treatment (H&E 400x) (C).
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Factors that cause liver tissue loss, such as viral diseases,
chemical damage, and surgical resections, trigger the replication of
hepatocytes, which have the ability to reproduce.23 The uncovering
of the complicated mechanisms of liver regeneration may herald
a new era in the treatment of patients with end-stage liver failure.
Inducing regeneration in liver transplant operations should help in
reducing donor morbidity and enable the receiver to heal quickly.
Substances that can affect liver regeneration positively or nega-
tively are one of themost attractive topics in modern science.24 EPOTable 2
Comparison of histopathological parameters among various groups.
Group A1 B1 P A2 B2 P A3 B3 P
MI (%) 3 5 .48 37 74 .0003 27 88 .0001
Double nuclei cells (%) 18 25 .28 19 22 .64 21 32 .018
PCNA (%) 27 30 .68 132 247 .0001 81 87 .63
PCNA: Ratio of marked cells with proliferating cell nuclear antigen, MI: Mitosis
index.was ﬁrst deﬁned as a hormone that regulates erythropoiesis in
mammals.25 EPO also has anti-inﬂammatory, antioxidant, anti-
apoptotic, and angiogenic properties.26 Bockhorn et al.26 found
that different doses of EPO signiﬁcantly increased liver regenera-
tion and survival in rats with partial hepatectomy and partial liver
transplantation, further studies are required to identify the optimal
dose. Klemm et al.27 found that when EPO was used in multiple
doses of 500e5000 IU/kg intravenously, it disrupted liver regen-
eration. There exist various studies regarding the method and
dosage of EPO usage in animals, some of them being 5000 IU EPO/
kg intravenously,26,27 4000 IU EPO/kg intraperitoneally,18
3000 IU EPO/kg subcutaneously,28and 500 IU EPO/kg intra-
venously.27In this study, we found that 3000 IU EPO/kg subcuta-
neously served to enhance the regeneration ability of the remaining
tissue after liver resection. A meaningful decrease in AST levels in
the serum of the EPO group was detected 24 h after hepatectomy.
This ﬁnding might reﬂect the anti-reperfusion injury ability rather
than the pro-regeneration ability of EPO. Interestingly, an increase
was observed in the AST values of the EPO group after 48 h, and an
insigniﬁcant decrease was observed after 72 h. When compared in
terms of RLW, we determined the RLW-increasing effect of EPO in
all three time periods. Sato et al.29 showed that mitotic activity in
the liver increases after partial hepatectomy. Greif et al.18 showed
that MI increases at days 2 and 4 under the effect of EPO. In our
study, it was seen that in the EPO group, there was a meaningful
increase in MI at 48 and 72 h. PCNA is a molecule weighing 36 kDa
that plays a role in the evolution process. PCNA is a cofactor of the
DNA polymerase, and it is also important in DNA synthesis and
repair.30,31 PCNA is a sensitive marker used in monitoring hepato-
cyte proliferation.32 In this study, in the EPO-treated group, PCNA
staining rates showed a statistically signiﬁcant increase at 48 h
compared with the hepatectomy group. Double nuclei cells and
cells with big hyperchromatic nuclei are not common in normal
non-regenerating liver cells, but they are clearly observed in
regenerating liver cells. In this study, a relative increase was
observed in the double nuclei cell number in the EPO-treated group
compared to the hepatectomy group in all three time periods, but
this increase was not signiﬁcant until 72 h. The limitation of this
study is that some parameters were studied to only a limited
extentowing to technical inadequacies. Another limitation is that
our study examined various parameters for a duration of only 3
days.
5. Conclusion
In this study, we observed that EPO affects liver regeneration by
increasing RLW in rats that hadmajor liver resection. We supported
this ﬁnding by showing that there also occurred increases in the
PCNA ratio, MI, and double nuclei cell number. Further molecular
studies should clarify the cellular mechanisms that cause the
positive effect of EPO on the liver regeneration ability.
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